MCL Literature Feed

A novel high-performance liquid chromatography-ultraviolet (HPLC-UV) assay was developed to measure pirtobrutinib levels, enabling therapeutic drug monitoring to potentially optimize dosing in MCL patients.

Optical genome mapping reveals diverse cryptic CCND1/2 rearrangements in ~10% of MCLs lacking the classic t(11;14), improving diagnosis and identifying high genomic complexity associated with poor outcomes.

Optical genome mapping detects additional clinically significant genomic aberrations in 8% of mantle cell lymphoma cases compared to standard cytogenetics, potentially improving risk stratification.

This large pooled analysis of 1280 trial patients validates progression within 24 months (POD24) as a robust indicator of poor survival, with rituximab maintenance reducing this risk.

In young, fit MCL patients undergoing frontline autotransplant, large clonal hematopoiesis clones (VAF ≥10%) at baseline are a novel biomarker for worse progression-free and overall survival.

The novel TBL1X inhibitor tegavivint induces DNA damage and synergizes with PARP inhibitors in preclinical MCL models, establishing TBL1X as a new therapeutic target for genomic instability.

This case report describes a rare CCND1-negative mantle cell lymphoma presenting atypically as leukemia, highlighting the need to consider this diagnosis despite the absence of the classic translocation.

Mantle cell lymphoma can present with prolymphocytic morphology, a diagnostic pitfall mimicking other lymphoproliferative disorders that requires ancillary testing like cyclin D1 IHC for accurate diagnosis.

This case of clonally-related composite DLBCL and CD5-negative MCL highlights a rare diagnostic challenge, emphasizing the need for comprehensive IHC panels to avoid misdiagnosing transformed lymphoma.

Genomic analysis of a single MCL patient identified specific mechanisms of resistance to PD-L1 blockade, providing crucial insights into why checkpoint inhibitors are often ineffective in this lymphoma.

This study validates a method using electronic health records to define real-world progression in MCL, providing a scalable endpoint that correlates strongly with overall survival for evidence generation.

In a retrospective, mixed-histology study including four MCL patients, splenectomy plus chemotherapy improved survival for aggressive lymphomas presenting with primary splenic involvement, suggesting a potential therapeutic role.

In a prospective cohort of primary GI lymphomas including MCL, routine endoscopic surveillance significantly improved overall survival by detecting relapse early, supporting its role in post-treatment management.

Integrated genomic and transcriptomic profiling identifies novel molecular subsets of MCL that predict patient outcomes, paving the way for risk-stratified therapy.

The protein TRIM24 regulates autophagy-mediated resistance to the proteasome inhibitor bortezomib, offering a potential new therapeutic target to overcome drug resistance in relapsed/refractory MCL.

A new CAR-T hematotoxicity score developed for B-ALL, which replaces ferritin with bone marrow burden, highlights the need to refine existing models like CAR-HT used in MCL for disease-specific prediction.

This retrospective Chinese study validates POD24 (progression within 24 months) as a powerful negative prognostic marker and incorporates it into a new model to better risk-stratify relapsed patients.

This case series identifies a rare intrasinusoidal bone marrow involvement pattern in MCL, highlighting a key diagnostic pitfall for pathologists and expanding the disease's recognized histopathological spectrum.

A Mendelian randomization study suggests a causal link between higher abundance of the gut bacterium Holdemania filiformis and a significantly reduced risk of developing mantle cell lymphoma.

In mantle cell lymphoma, MRD assessment is most predictive of survival after four induction cycles, while rapid clearance within two cycles offers no prognostic benefit, guiding risk stratification.

A high-risk, TP53-mutated MCL patient achieved a durable 2-year complete remission with brexucabtagene autoleucel, but developed prolonged severe cytopenias and clonal hematopoiesis, highlighting efficacy and toxicity.

A new flow cytometry score incorporating CD19/CD20 ratio, CD200, and CD43 improves diagnostic sensitivity for differentiating MCL from CLL/SLL, a common and critical clinical challenge.

This modeling study in CLL suggests lower ibrutinib doses (140-280mg) maintain full BTK occupancy, implying potential for dose reduction to manage toxicity in MCL patients without compromising efficacy.

This preclinical CLL study validates 5-lipoxygenase inhibitors for disrupting tumor-microenvironment adhesion, reinforcing this novel mechanism, previously identified by the authors, as a potential therapeutic strategy for MCL.

This review summarizes the genomic, molecular, and pathological variations in MCL, highlighting how this biological heterogeneity impacts risk stratification, prognosis, and the development of personalized therapies.

A cross-validated, lymphoma-tailored NGS panel demonstrates high accuracy, providing a framework for implementing standardized genomic testing for prognostication in routine MCL clinical practice.

This systematic review finds all AI models for lymphoma histopathology, including MCL, have a high risk of bias, questioning their reported high accuracy and current clinical readiness.

A case of TP53-mutated, indolent non-nodal MCL suggests this high-risk marker may not mandate immediate therapy in this specific subtype, supporting a watch-and-wait approach.

This review synthesizes clinical, molecular, and genomic markers to define high-risk MCL, guiding risk-stratified treatment and highlighting future therapies like bispecifics for this poor-prognosis population.

A rare case of extranodal MCL presenting as bilateral adrenal masses showed avidity on both FDG and DOTATATE PET/CT, expanding the differential diagnosis for adrenal lesions.